At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,368 enrolled
Drug / intervention
JARDIANCE 10mg +1 moredrug
Likely dose
JARDIANCE 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating JARDIANCE 10mg and JARDIANCE 25mg for Diabetes Mellitus, Type 2. Completed, enrolled 3,368 participants across 1 site.
Detailed Summary
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartAug 2016
Primary CompletionApr 2020
TodayJul 2026
First PostedJul 29, 2016
Enrollment StartAug 10, 2016
Primary CompletionApr 17, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.9 years ago
Interventions
JARDIANCE 10mgdrug
T2DM with JARDIANCE 10mg
JARDIANCE 25mgdrug
MT2DM with JARDIANCE 25mgax